Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.54 |
| ▸ | STING1 | Q86WV6 | 6/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HINT1 | P49773 | 1/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.46 |
| ▸ | TK1 | P04183 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24703672 | 1.00 | ADORA3 (0.54) | ADORA3STING1PDE3BPDE3AHPGD | |
| SCHEMBL19820350 | 1.00 | ADORA3 (0.54) | ADORA3STING1PDE3BPDE3AHPGD | |
| SCHEMBL14929377 | 1.00 | ADORA3 (0.54) | ADORA3STING1PDE3BPDE3AHPGD | |
| SCHEMBL3033632 | 1.00 | ADORA3 (0.54) | ADORA3STING1PDE3BPDE3AHPGD | |
| SCHEMBL27040 | 1.00 | ADORA3 (0.54) | ADORA3STING1PDE3BPDE3AHPGD | |
| SCHEMBL25758007 | 0.90 | ADORA3 (0.52) | ADORA3STING1PDE3BPDE3AHPGD | |
| SCHEMBL5995487 | 0.90 | ADORA3 (0.52) | ADORA3STING1PDE3BPDE3AHPGD | |
| SCHEMBL18574172 | 0.90 | ADORA3 (0.50) | ADORA3STING1PDE3BPDE3AHPGD | |
| SCHEMBL14946321 | 0.90 | ADORA3 (0.50) | ADORA3STING1PDE3BPDE3AHPGD | |
| SCHEMBL14853672 | 0.90 | ADORA3 (0.50) | ADORA3STING1PDE3BPDE3AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022006368-A2 | TRINUCLEOTIDE CAP ANALOGS, PREPARATION AND USES THEREOF | Life Technologies Corporation (US) | 2022-01-06 | — | — | WO | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | ADORA3 103/4885STING1 413/4885PDE3B 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.